Interface-Based Design of High-Affinity Affibody Ligands for the Purification of RBD from Spike Proteins.

Siyuan Song, Qinghong Shi

Abstract read

In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Siyuan SongDepartment of Biochemical Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin 300350, China.

Qinghong ShiDepartment of Biochemical Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin 300350, China.

Funding

Foundation for Innovative Research Groups of the National Natural Science Foundation of China 21621004National Key Research and Development Program of China 2021YFC2103402National Natural Science Foundation of China 21878221

6 · The paper itself

Abstract

The outbreak of coronavirus disease 2019 (COVID-19) has sparked an urgent demand for advanced diagnosis and vaccination worldwide. The discovery of high-affinity ligands is of great significance for vaccine and diagnostic reagent manufacturing. Targeting the receptor binding domain (RBD) from the spike protein of severe acute respiratory syndrome-coronavirus 2, an interface at the outer surface of helices on the Z domain from protein A was introduced to construct a virtual library for the screening of Z

Indexed as

COVID-19HumansLigandsMolecular Docking SimulationSpike Glycoprotein, CoronavirusLigandsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2affibodyaffinity chromatographybinding affinityligand designmolecular dynamics simulationreceptor binding domain

Identifiers

PMID37687186

DOI10.3390/molecules28176358

PMCPMC10489752

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.